SCHEMBL272092

SCHEMBL272092

Cc1ccccc1-c1ccc(C(=O)O)cc1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 2/20 0.56
▸ PTPRC P08575 2/20 0.55
▸ SRD5A2 P31213 2/20 0.51
▸ POLB P06746 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ SRD5A1 P18405 1/20 0.51
▸ PTPN7 P35236 2/20 0.51
▸ PPM1G O15355 1/20 0.51
▸ PTPN1 P18031 1/20 0.51
▸ PTPN5 P54829 1/20 0.51
▸ PTPRO Q16827 1/20 0.51
▸ PTPN22 Q9Y2R2 1/20 0.51
▸ MYC P01106 2/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ NR1H4 Q96RI1 3/20 0.49
▸ PLA2G7 Q13093 2/20 0.47
▸ MCL1 Q07820 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL68014 0.90 ALDH1A1 (0.57) TTRPTPRCPOLBKMT2APTPN7
SCHEMBL2805441 0.89 TTR (0.53) TTRPTPRCSRD5A2POLBKMT2A
SCHEMBL1712772 0.89 MYC (0.56) TTRPTPRCSRD5A2POLBKMT2A
Hydrochloric Acid SCHEMBL4352471 0.88 ALDH1A1 (0.56) TTRPTPRCPOLBKMT2APTPN7
SCHEMBL2771422 0.87 PTPRC (0.54) TTRPTPRCSRD5A2POLBKMT2A
SCHEMBL2777510 0.87 TTR (0.51) TTRPTPRCSRD5A2POLBKMT2A
SCHEMBL4915994 0.87 TTR (0.51) TTRPTPRCSRD5A2POLBKMT2A
SCHEMBL629880 0.87 MYC (0.54) TTRPTPRCPOLBKMT2AMYC
SCHEMBL4849736 0.86 TTR (0.50) TTRPTPRCSRD5A2POLBKMT2A
SCHEMBL12388484 0.86 TTR (0.50) TTRPTPRCSRD5A2POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9732032-B2 3-aminocyclopentane carboxamide derivatives MERCK PATENT GMBH (DE) 2017-08-15 — — US claimed
CN-104797553-B 3 aminocyclopentanecarasxamides derivatives 默克专利股份公司 2017-07-21 — — CN claimed
EP-2920146-B1 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-28 — — EP claimed
US-20160264517-A1 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES MERCK PATENT GMBH (DE) 2016-09-15 — — US claimed
EP-2920146-A1 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES Merck Patent GmbH (DE) 2015-09-23 — — EP claimed
CN-104797553-A 3-aminocyclopentane carboxamide derivatives MERCK PATENT GMBH 2015-07-22 — — CN claimed
WO-2014075754-A1 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES MERCK PATENT GMBH (DE) 2014-05-22 — — WO claimed
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 — — US disclosed
EP-2414341-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-09-13 — — EP disclosed
EP-2414341-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-09-13 — — EP disclosed
US-9732032-B2 3-aminocyclopentane carboxamide derivatives MERCK PATENT GMBH (DE) 2017-08-15 — — US disclosed
CN-104797553-B 3 aminocyclopentanecarasxamides derivatives 默克专利股份公司 2017-07-21 — — CN disclosed
EP-2414342-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-05-31 — — EP disclosed
US-20030212012-A1 Pharmaceutically active pyrrolidine derivatives MERCK SERONO SA (CH) 2003-11-13 — — US disclosed
EP-1268418-A1 PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS Applied Research Systems ARS Holding N.V. (AN) 2003-01-02 — — EP disclosed
EP-1268419-A1 PYRROLIDINE DERIVATIVES USEFUL AS BAX INHIBITORS Applied Research Systems ARS Holding N.V. (AN) 2003-01-02 — — EP disclosed
WO-2002102799-A2 PYRROLIDINE OXADIAZOLE- AND THIADIAZOLE OXIME DERIVATIVES BEING OXYTOCIN RECEPTOR ANTAGONISTS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2002-12-27 — — WO disclosed
WO-2002074741-A1 PYRROLIDINE ESTER DERIVATIVES WITH OXYTOCIN MODULATING ACITVITY APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) 2002-09-26 — — WO disclosed
WO-2001074769-A1 PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-10-11 — — WO disclosed
WO-2001072705-A1 PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-10-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212012-A1 Pharmaceutically active pyrrolidine derivatives OXTR, CNR1, PRLHR TTR 4336/4885PTPRC 1936/4885SRD5A2 73/4885
US-20160264517-A1 3-AMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES FADS1, FASN, FFAR3 TTR 4454/4885PTPRC 2987/4885SRD5A2 921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback